Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
Strata Skin Sciences Inc (SSKN) provides innovative medical technologies for dermatology practices, specializing in excimer laser treatments for conditions like psoriasis and vitiligo. This news hub offers investors and healthcare professionals timely updates on SSKN's financial developments, product innovations, and strategic partnerships.
Access official press releases covering quarterly earnings, FDA clearances, clinical study results, and partnership expansions with dermatology clinics. Our curated collection simplifies tracking SSKN's progress in advancing in-office phototherapy solutions and its unique recurring revenue model.
Discover updates about the XTRAC® excimer laser system, VTRAC™ lamp technologies, and SSKN's practice support programs. Content is organized chronologically for quick reference, with clear sourcing for regulatory filings and corporate announcements.
Bookmark this page to stay informed about SSKN's position in the $12B+ global dermatology devices market. Verify all information directly with SEC filings or company communications before making financial decisions.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced preliminary first-quarter 2023 revenue estimates between $7.3 million and $7.8 million, marking the strongest results for the period since 2016. The company successfully placed 44 TheraClear®X devices, contributing to over 3,000 treatments sold since the product's launch in January 2023. Moreover, STRATA has converted 86 Pharos® accounts to XTRAC® devices, enhancing its presence in the eczema-laser market. CEO Bob Moccia expressed optimism about the sales momentum and its anticipated impact on revenues for 2023. The unaudited results are subject to revision, with full financial results expected in May 2023.
STRATA Skin Sciences, a medical technology firm, reported a record revenue of $36.2 million for 2022, up 21% from 2021, with fourth-quarter revenue at $10.6 million (17% increase year-over-year). Global recurring revenue reached $23 million for the year. Despite these gains, the company posted a net loss of $5.5 million for 2022 compared to a $2.7 million loss in 2021. The installed base of XTRAC® devices rose to 909. Looking forward, STRATA projects revenue in 2023 to be between $38 million and $40 million. The company aims to grow its market share while launching new marketing initiatives.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology firm focused on dermatologic treatments, will release its fourth-quarter 2022 financial results and Form 10-K on March 31, 2023. The company will hold a conference call at 8:30 AM EDT on the same day to discuss financial results and provide a corporate update. Key products include the XTRAC® and Pharos® excimer lasers, VTRAC® lamp systems, and the new TheraClear® X Acne Therapy System. STRATA operates a unique Partnership Program whereby practices are charged per treatment rather than for equipment purchases, ensuring support and marketing assistance.
FAQ
What is the current stock price of Strata Skin Sciences (SSKN)?
What is the market cap of Strata Skin Sciences (SSKN)?
